[1]
T.
Ito, M.J. Young, R. Li, S. Jain, A. Wernitznig, J.M. Krill-Burger, C.T.
Lemke, D. Monducci, D.J. Rodriguez, L. Chang, S. Dutta, D. Pal, B.R.
Paolella, M.V. Rothberg, D.E. Root, C.M. Johannessen, L. Parida, G.
Getz, F. Vazquez, J.G. Doench, M. Zamanighomi, W.R. Sellers,
Paralog knockout profiling identifies
DUSP4 and
DUSP6 as a digenic
dependence in MAPK
pathway-driven cancers, Nat Genet. 53 (2021) 1664–1672. doi:
10.1038/s41588-021-00967-z.
[2]
J.M. García-Martínez, S. Wang, C. Weishaeupl,
A. Wernitznig, P. Chetta, C. Pinto, J. Ho, D. Dutcher, P.N. Gorman, R.
Kroe-Barrett, J. Rinnenthal, C. Giragossian, M.A. Impagnatiello, I.
Tirapu, F. Hilberg, N. Kraut, M. Pearson, K.P. Kuenkele,
Selective Tumor
Cell Apoptosis and Tumor
Regression in
CDH17-Positive
Colorectal Cancer Models using
BI 905711, a Novel
Liver-Sparing
TRAILR2
Agonist, Mol Cancer Ther. 20 (2021) 96–108. doi:
10.1158/1535-7163.MCT-20-0253.
[3]
D.J. Lamb, A. Rust, A. Rudisch, T. Glüxam, N.
Harrer, H. Machat, I. Christ, F. Colbatzky, A. Wernitznig, A. Osswald,
W. Sommergruber,
Inhibition of
SYK kinase does not confer a
pro-proliferative or pro-invasive phenotype in breast epithelium or
breast cancer cells, Oncotarget. 11 (2020) 1257–1272. doi:
10.18632/oncotarget.27545.
[4]
D.
Wernitznig, S.M. Meier-Menches, K. Cseh, S. Theiner, D. Wenisch, A.
Schweikert, M.A. Jakupec, G. Koellensperger, A. Wernitznig, W.
Sommergruber, B.K. Keppler,
Plecstatin-1 induces an immunogenic cell
death signature in colorectal tumour spheroids, Metallomics. 12
(2020) 2121–2133. doi:
10.1039/d0mt00227e.
[5]
D.
Wernitznig, K. Kiakos, G. Del Favero, N. Harrer, H. Machat, A. Osswald,
M.A. Jakupec, A. Wernitznig, W. Sommergruber, B.K. Keppler,
First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an
immunogenic cell death signature in colorectal spheroids in vitro,
Metallomics. (2019) –. doi:
10.1039/C9MT00051H.
[6]
S.
Lieb, S. Blaha-Ostermann, E. Kamper, J. Rippka, C. Schwarz, K.
Ehrenhofer-Wolfer, A. Schlattl, A. Wernitznig, J.J. Lipp, K. Nagasaka,
P. vanDerLelij, G. Bader, M. Koi, A. Goel, R.A. Neumuller, J.M. Peters,
N. Kraut, M.A. Pearson, M. Petronczki, S. Wohrle,
Werner syndrome helicase is a selective
vulnerability of microsatellite instability-high tumor cells,
Elife. 8 (2019). doi:
10.7554/eLife.43333.
[7]
M.
Streit, S. Gratzl, H. Stitz, A. Wernitznig, T. Zichner, C. Haslinger,
Ordino: a visual cancer analysis tool for ranking
and exploring genes, cell lines and tissue samples,
Bioinformatics. (2019). doi:
10.1093/bioinformatics/btz009.
[8]
T.
Zoranovic, J. Manent, L. Willoughby, R. Matos de Simoes, J.E. La Marca,
S. Golenkina, X. Cuiping, S. Gruber, B. Angjeli, E.E. Kanitz, S.J.F.
Cronin, G.G. Neely, A. Wernitznig, P.O. Humbert, K.J. Simpson, C.S.
Mitsiades, H.E. Richardson, J.M. Penninger, A genome-wide drosophila
epithelial tumorigenesis screen identifies tetraspanin 29Fb as an
evolutionarily conserved suppressor of ras-driven cancer, PLOS Genetics.
14 (2018) 1–36. doi:
10.1371/journal.pgen.1007688.
[9]
M.P. Sanderson, M.H. Hofmann, P. Garin-Chesa,
N. Schweifer, A. Wernitznig, S. Fischer, A. Jeschko, R. Meyer, J. Moll,
T. Pecina, H. Arnhof, U. Weyer-Czernilofsky, S.K. Zahn, G.R. Adolf, N.
Kraut,
The
IGF1R/INSR
inhibitor BI 885578 selectively inhibits
growth of IGF2-overexpressing
colorectal cancer tumors and potentiates the efficacy of
anti-VEGF
therapy, Mol. Cancer Ther. 16 (2017) 2223–2233. doi:
10.1158/1535-7163.MCT-17-0336.
[10]
C.
Unger, N. Kramer, D. Unterleuthner, M. Scherzer, A. Burian, A. Rudisch,
M. Stadler, M. Schlederer, D. Lenhardt, A. Riedl, S. Walter, A.
Wernitznig, L. Kenner, M. Hengstschlager, J. Schuler, W. Sommergruber,
H. Dolznig,
Stromal-derived
IGF2 promotes colon cancer
progression via paracrine and autocrine mechanisms, Oncogene. 36
(2017) 5341–5355. doi:
10.1038/onc.2017.116.
[11]
A.
Rudisch, M.R. Dewhurst, L.G. Horga, N. Kramer, N. Harrer, M. Dong, H.
van der Kuip, A. Wernitznig, A. Bernthaler, H. Dolznig, W. Sommergruber,
High
EMT Signature
Score of Invasive
Non-Small Cell Lung
Cancer
(NSCLC)
Cells Correlates with
NFκB Driven
Colony-Stimulating Factor 2
(CSF2/GM-CSF)
Secretion by Neighboring Stromal
Fibroblasts, PLoS ONE. 10 (2015) e0124283.
[12]
D.
Rudolph, M.A. Impagnatiello, C. Blaukopf, C. Sommer, D.W. Gerlich, M.
Roth, U. Tontsch-Grunt, A. Wernitznig, F. Savarese, M.H. Hofmann, C.
Albrecht, L. Geiselmann, M. Reschke, P. Garin-Chesa, J. Zuber, J. Moll,
G.R. Adolf, N. Kraut, Efficacy and
mechanism of action of volasertib, a potent and selective inhibitor of
Polo-like kinases, in preclinical models of acute myeloid
leukemia, J. Pharmacol. Exp. Ther. 352 (2015) 579–589.
[13]
S.
Glatt, D. Halbauer, S. Heindl, A. Wernitznig, D. Kozina, K.C. Su, C.
Puri, P. Garin-Chesa, W. Sommergruber, hGPR87 contributes
to viability of human tumor cells, Int. J. Cancer. 122 (2008)
2008–2016.
[14]
K.
Aigner, B. Dampier, L. Descovich, M. Mikula, A. Sultan, M. Schreiber, W.
Mikulits, T. Brabletz, D. Strand, P. Obrist, W. Sommergruber, N.
Schweifer, A. Wernitznig, H. Beug, R. Foisner, A. Eger, The transcription factor
ZEB1
(deltaEF1) promotes tumour cell
dedifferentiation by repressing master regulators of epithelial
polarity, Oncogene. 26 (2007) 6979–6988.
[15]
K.
Aigner, L. Descovich, M. Mikula, A. Sultan, B. Dampier, S. Bonne, F. van
Roy, W. Mikulits, M. Schreiber, T. Brabletz, W. Sommergruber, N.
Schweifer, A. Wernitznig, H. Beug, R. Foisner, A. Eger, The transcription factor
ZEB1
(deltaEF1) represses Plakophilin
3 during human cancer progression, FEBS Lett. 581 (2007)
1617–1624.
[16]
V.
Weber, A. Wernitznig, G. Hager, M. Harata, P. Frank, U. Wintersberger,
Purification and nucleic-acid-binding
properties of a Saccharomyces cerevisiae protein involved
in the control of ploidy, Eur. J. Biochem. 249 (1997)
309–317.